Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Brief Summary: This phase I/II trial studies the side effects and best dose of genetically engineered lymphocyte therapy and to see how well it works after peripheral blood stem cell transplant (PBSCT) in treating patients with high-risk, intermediate-grade, B-cell non-Hodgkin lymphoma (NHL). Genetically engineered lymphocyte therapy may stimulate the immune system in different ways and stop cancer cells from growing. Giving rituximab together with chemotherapy before a PBSCT stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim (G-CSF), or plerixafor helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving genetically engineered lymphocyte therapy after PBSCT may be an effective treatment for NHL.


Options:
A: Arm Label: Treatment (cellular adoptive immunotherapy following PBSCT); Type: EXPERIMENTAL; Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation, Biological: Filgrastim, Biological: Genetically Engineered Lymphocyte Therapy, Other: Laboratory Biomarker Analysis, Procedure: Peripheral Blood Stem Cell Transplantation, Drug: Plerixafor, Biological: Rituximab | Intervention Type: PROCEDURE; Name: Autologous Hematopoietic Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Genetically Engineered Lymphocyte Therapy; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: DRUG; Name: Plerixafor; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT)
B: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Combination Product: CLBR001 and SWI019 | Intervention Type: COMBINATION_PRODUCT; Name: CLBR001 and SWI019; Assigned to Arm(s): Dose Escalation
C: Intervention Type: BIOLOGICAL; Name: chimeric antigen receptor T cells; Assigned to Arm(s): N/A
D: Arm Label: ACTR707 in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR707, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR707; Assigned to Arm(s): ACTR707 in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR707 in combination with rituximab

Answer: A